This approach identifies potential biomarkers of high-grade ovarian cancer, suggesting new targets for treatment.
The identification of these hub genes and pathways may represent an important step forward in our understanding of HGOC. While down-regulated genes may also hold biological significance, their analysis was beyond the scope of this study and warrants future investigation. Further experimental validation is needed to confirm the roles of the identified genes in disease pathogenesis and their potential as biomarkers and therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Kahraman et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: